Protopic

Land: Europäische Union

Sprache: Englisch

Quelle: EMA (European Medicines Agency)

Kaufe es jetzt

Wirkstoff:

tacrolimus

Verfügbar ab:

LEO Pharma A/S

ATC-Code:

D11AH01

INN (Internationale Bezeichnung):

tacrolimus

Therapiegruppe:

Other dermatological preparations

Therapiebereich:

Dermatitis, Atopic

Anwendungsgebiete:

Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Produktbesonderheiten:

Revision: 26

Berechtigungsstatus:

Authorised

Berechtigungsdatum:

2002-02-27

Gebrauchsinformation

                                39
B. PACKAGE LEAFLET
40
PACKAGE LEAFLET: INFORMATION FOR THE USER
PROTOPIC 0.03% OINTMENT
tacrolimus monohydrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Protopic is and what it is used for
2.
What you need to know before you use Protopic
3.
How to use Protopic
4.
Possible side effects
5.
How to store Protopic
6.
Contents of the pack and other information
1.
WHAT PROTOPIC IS AND WHAT IT IS USED FOR
The active substance of Protopic, tacrolimus monohydrate, is an
immunomodulating agent.
Protopic 0.03% ointment is used to treat moderate to severe atopic
dermatitis (eczema) in adults who
are not adequately responsive to or are intolerant of conventional
therapies such as topical
corticosteroids and in children (2 years of age and older) who failed
to respond adequately to
conventional therapies such as topical corticosteroids.
Once moderate to severe atopic dermatitis is cleared or almost cleared
after up to 6 weeks treatment of
a flare, and if you are experiencing frequent flares (i.e. 4 or more
per year), it may be possible to
prevent flares coming back or prolong the time you are free from
flares by using Protopic 0.03%
ointment twice weekly.
In atopic dermatitis, an over-reaction of the skin’s immune system
causes skin inflammation
(itchiness, redness, dryness). Protopic alters the abnormal immune
response and relieves the skin
inflammation and the itch.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PROTOPIC
DO NOT USE PROTOPIC
•
If you are allergic to tacrolimus or any of the other ingredi
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Fachinformation

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Protopic 0.03% ointment
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 g of Protopic 0.03% ointment contains 0.3 mg of tacrolimus as
tacrolimus monohydrate (0.03%).
Excipient with known effect
Butylhydroxytoluene (E321) 15 micrograms/g ointment.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Ointment
A white to slightly yellowish ointment.
_ _
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Protopic 0.03% ointment is indicated in adults, adolescents and
children from the age of 2 years.
Flare treatment
_Adults and adolescents (16 years of age and above)_
Treatment of moderate to severe atopic dermatitis in adults who are
not adequately responsive to or
are intolerant of conventional therapies such as topical
corticosteroids.
_Children (2 years of age and above) _
Treatment of moderate to severe atopic dermatitis in children who
failed to respond adequately to
conventional therapies such as topical corticosteroids.
Maintenance treatment
Treatment of moderate to severe atopic dermatitis for the prevention
of flares and the prolongation of
flare-free intervals in patients experiencing a high frequency of
disease exacerbations (i.e. occurring 4
or more times per year) who have had an initial response to a maximum
of 6 weeks treatment of twice
daily tacrolimus ointment (lesions cleared, almost cleared or mildly
affected).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Protopic treatment should be initiated by physicians with experience
in the diagnosis and treatment of
atopic dermatitis.
Protopic is available in two strengths, Protopic 0.03% and Protopic
0.1% ointment.
Posology
Flare treatment
Protopic can be used for short-term and intermittent long-term
treatment. Treatment should not be
continuous on a long-term basis.
Protopic treatment should begin at the first appearance of signs and
symptoms. Each affected region of
the skin should be treated with Protopic until lesions are cleared,
almost cleared or mildly a
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Dokumente in anderen Sprachen

Gebrauchsinformation Gebrauchsinformation Bulgarisch 13-02-2024
Fachinformation Fachinformation Bulgarisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Bulgarisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Spanisch 13-02-2024
Fachinformation Fachinformation Spanisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Tschechisch 13-02-2024
Fachinformation Fachinformation Tschechisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Tschechisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Dänisch 13-02-2024
Fachinformation Fachinformation Dänisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Deutsch 13-02-2024
Fachinformation Fachinformation Deutsch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Estnisch 13-02-2024
Fachinformation Fachinformation Estnisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Griechisch 13-02-2024
Fachinformation Fachinformation Griechisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Griechisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Französisch 13-02-2024
Fachinformation Fachinformation Französisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Französisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Italienisch 13-02-2024
Fachinformation Fachinformation Italienisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Italienisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Lettisch 13-02-2024
Fachinformation Fachinformation Lettisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Litauisch 13-02-2024
Fachinformation Fachinformation Litauisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Litauisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Ungarisch 13-02-2024
Fachinformation Fachinformation Ungarisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Ungarisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Maltesisch 13-02-2024
Fachinformation Fachinformation Maltesisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Maltesisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Niederländisch 13-02-2024
Fachinformation Fachinformation Niederländisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Niederländisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Polnisch 13-02-2024
Fachinformation Fachinformation Polnisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Portugiesisch 13-02-2024
Fachinformation Fachinformation Portugiesisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Portugiesisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Rumänisch 13-02-2024
Fachinformation Fachinformation Rumänisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Rumänisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Slowakisch 13-02-2024
Fachinformation Fachinformation Slowakisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Slowakisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Slowenisch 13-02-2024
Fachinformation Fachinformation Slowenisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Slowenisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Finnisch 13-02-2024
Fachinformation Fachinformation Finnisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Schwedisch 13-02-2024
Fachinformation Fachinformation Schwedisch 13-02-2024
Öffentlichen Beurteilungsberichts Öffentlichen Beurteilungsberichts Schwedisch 16-08-2011
Gebrauchsinformation Gebrauchsinformation Norwegisch 13-02-2024
Fachinformation Fachinformation Norwegisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Isländisch 13-02-2024
Fachinformation Fachinformation Isländisch 13-02-2024
Gebrauchsinformation Gebrauchsinformation Kroatisch 13-02-2024
Fachinformation Fachinformation Kroatisch 13-02-2024

Suchen Sie nach Benachrichtigungen zu diesem Produkt

Dokumentverlauf anzeigen